clinical trial

[PharmaTher Holdings Ltd.] PharmaTher Holdings Ltd. announced that the US FDA has accepted an investigator-initiated IND application to proceed with a Phase II clinical trial evaluating ketamine in the treatment of Amyotrophic Lateral Sclerosis (ALS).

[Fate Therapeutics, Inc.] Fate Therapeutics, Inc. announced that the US FDA has cleared the company’s Investigational New Drug application for FT536, an off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor NK cell product candidate.

[Starton Therapeutics, Inc.] Starton Therapeutics, Inc. announced that it has received its first Clinical Trial Authorization in the Netherlands to initiate a Phase I study evaluating STAR-LLD, a continuous delivery lenalidomide in development to expand the standard of care for the most common blood cancers, multiple myeloma and chronic lymphocytic leukemia, bioavailability in human subjects.

[BioAtla, Inc. (PR Newswire, Inc.)] BioAtla, Inc. announced that it has entered into a clinical collaboration with Bristol Myers Squibb to investigate BioAtla's two lead CAB-ADC candidates, BA3011 and BA3021, in combination with Bristol Myers Squibb's anti-PD-1 therapy nivolumab.

[Rafael Pharmaceuticals, Inc. (Globe Newswire, Inc.)] Rafael Pharmaceuticals, Inc. announced the completion of the first cohort of dose escalation with no DLT in the APOLLO 613 Phase I/II clinical trial of devimistat in combination with hydroxychloroquine in patients with relapsed clear cell sarcoma.

[Emerald Health Pharmaceuticals, Inc. (GlobeNewswire, Inc.)] Emerald Health Pharmaceuticals, Inc. received clearance of its Investigational New Drug (IND) application by the FDA to begin enrolling patients in its Phase IIa clinical trial of EHP-101 for certain relapsing forms of multiple sclerosis (MS), specifically relapsing-remitting MS and active secondary progressive MS.